{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:50:22Z","timestamp":1782276622420,"version":"3.54.5"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is a malignancy characterised by high incidence and mortality rates, with China accounting for over 50% of new cases and deaths globally. The prevention and treatment of HCC remain formidable challenges, primarily due to pronounced tumour heterogeneity and a complex immune microenvironment. Recent advances in immunotherapy have highlighted the critical role of tumour antigen-specific T cells (TASCs) in the management of HCC. This review systematically examines the mechanisms underlying TASCs function, recent advances in HCC research, and the clinical significance of TASCs detection. It further analyses current challenges in HCC immunotherapy and offers a theoretical foundation and prospective directions for the development of combination and personalised therapies targeting TASCs.<\/jats:p>","DOI":"10.3389\/fonc.2026.1704905","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:44:25Z","timestamp":1782276265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The mechanism of action, clinical significance, and research progress of tumor antigen-specific T cells in the treatment of HCC"],"prefix":"10.3389","volume":"16","author":[{"given":"Liu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hongwei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol Supplements"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i6.1054","article-title":"Immunotherapy for hepatocellular carcinoma: Current status and future perspectives","volume":"29","author":"Mandlik","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.09","article-title":"Basic liver immunology","volume":"13","author":"Gao","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell Dysfunction in Cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B11","first-page":"91","article-title":"MHC and T cell development","volume":"1","author":"Viret","year":"1999","journal-title":"Rev Immunogenet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13811","article-title":"Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-025-02314-w","article-title":"Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response","volume":"24","author":"Zeng","year":"2025","journal-title":"Mol Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0376-4","article-title":"Targeting CD39 in cancer","volume":"20","author":"Moesta","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v16.i10.1158","article-title":"Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients","volume":"16","author":"Cao","year":"2024","journal-title":"World J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-47189-7_9","article-title":"Adenosine Signaling in the Tumor Microenvironment","volume":"1270","author":"Antonioli","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0406-2","article-title":"Lactate modulation of immune responses in inflammatory versus tumour microenvironments","volume":"21","author":"Certo","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0468-x","article-title":"Human cancer germline antigen-specific cytotoxic T cell\u2014what can we learn from patient","volume":"17","author":"Hamid","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.017.","article-title":"Antibodies Against Immune Checkpoint Molecules RestoreFunctions of Tumor-Infiltrating T Cells in HepatocellularCarcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1453412","article-title":"Therapeutic advances in hepatocellular carcinoma: an update from the 2024 ASCO annual meeting","volume":"14","author":"Yang","year":"2024","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30212","article-title":"Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma","volume":"69","author":"Inada","year":"2019","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1053\/j.gastro.2017.02.001","article-title":"Association Between High-Avidity T-Cell Receptors, Induced by \u03b1-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma","volume":"152","author":"Nakagawa","year":"2017","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1129483","article-title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0110","article-title":"Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC","volume":"4","author":"Gabrielson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1758835919862692","DOI":"10.1177\/1758835919862692","article-title":"Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives","volume":"11","author":"Xu","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1186\/s12885-021-08720-9","article-title":"Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages","volume":"21","author":"Zang","year":"2021","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/egh.09.50","article-title":"Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus","volume":"3","author":"Wang","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105267","article-title":"Genetic and phenotypic difference in CD8 + T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma","volume":"56","author":"Wang","year":"2018","journal-title":"J Med Genet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Erratum to \u201cTransient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J Hepatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2021.06.013","article-title":"Non-terminally exhausted tumor-resident memory HBV-specific Tcell responses correlate with relapse-free survival in hepatocellular carcinoma","volume":"54","author":"Cheng","year":"2021","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(03)00292-7","article-title":"Small-molecule inhibitors of PD-1\/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells","volume":"8","author":"Skalniak","year":"2017","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cclet.2023.108202","article-title":"CAR-T cells for cancer immunotherapy","volume":"34","author":"Xie","year":"2023","journal-title":"Chin Chem Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.971959","article-title":"Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy","volume":"12","author":"Hak","year":"2022","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0468-x","article-title":"Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient","volume":"17","author":"Abd Hamid","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"100777","DOI":"10.1016\/j.tranon.2020.100777","article-title":"Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation","volume":"13","author":"Kitahara","year":"2020","journal-title":"Transl Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12967-017-1165-0","article-title":"Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy","volume":"15","author":"Han","year":"2017","journal-title":"J Transl Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00262-020-02734-1","article-title":"Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma","volume":"70","author":"Leuchte","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B46","article-title":"Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation","volume":"74","author":"Panagiota","year":"2025","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11175075","article-title":"Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis","volume":"11","author":"Liu","year":"2022","journal-title":"J Clin Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1704905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:44:29Z","timestamp":1782276269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1704905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":47,"alternative-id":["10.3389\/fonc.2026.1704905"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1704905","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1704905"}}